Royalty Sale Purchase Of Stock from 2010 to 2024

RPRX Stock  USD 25.54  0.14  0.55%   
Royalty Pharma Sale Purchase Of Stock yearly trend continues to be fairly stable with very little volatility. Sale Purchase Of Stock is likely to outpace its year average in 2024. During the period from 2010 to 2024, Royalty Pharma Sale Purchase Of Stock regression line of annual values had r-squared of  0.02 and arithmetic mean of  711,681,463. View All Fundamentals
 
Sale Purchase Of Stock  
First Reported
2016-12-31
Previous Quarter
-80 M
Current Value
-97 M
Quarterly Volatility
78.4 M
 
Covid
Check Royalty Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Royalty Pharma's main balance sheet or income statement drivers, such as Interest Expense of 196.5 M, Total Revenue of 2.5 B or Research Development of 57.5 M, as well as many indicators such as Price To Sales Ratio of 5.07, Dividend Yield of 0.0361 or PTB Ratio of 3.83. Royalty financial statements analysis is a perfect complement when working with Royalty Pharma Valuation or Volatility modules.
  
Check out the analysis of Royalty Pharma Correlation against competitors.

Latest Royalty Pharma's Sale Purchase Of Stock Growth Pattern

Below is the plot of the Sale Purchase Of Stock of Royalty Pharma Plc over the last few years. It is Royalty Pharma's Sale Purchase Of Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Royalty Pharma's overall financial position and show how it may be relating to other accounts over time.
Sale Purchase Of Stock10 Years Trend
Pretty Stable
   Sale Purchase Of Stock   
       Timeline  

Royalty Sale Purchase Of Stock Regression Statistics

Arithmetic Mean711,681,463
Geometric Mean0.00
Coefficient Of Variation435.08
Mean Deviation1,490,575,805
Median147,000
Standard Deviation3,096,380,928
Sample Variance9587574.8T
Range12.4B
R-Value0.15
Mean Square Error10091512.6T
R-Squared0.02
Significance0.59
Slope104,135,617
Total Sum of Squares134226047.9T

Royalty Sale Purchase Of Stock History

2024-289.5 M
2023-304.8 M
2022-144.1 M
2021-479.6 M
202011.9 B
2019-4.3 M

About Royalty Pharma Financial Statements

Royalty Pharma investors use historical fundamental indicators, such as Royalty Pharma's Sale Purchase Of Stock, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Royalty Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Sale Purchase Of Stock-304.8 M-289.5 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Royalty Stock Analysis

When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.